Marshall Wace LLP Raises Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Marshall Wace LLP boosted its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 24.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 825,905 shares of the medical research company’s stock after buying an additional 163,056 shares during the period. Marshall Wace LLP owned approximately 1.60% of Charles River Laboratories International worth $170,615,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the company. Czech National Bank boosted its position in Charles River Laboratories International by 0.5% in the first quarter. Czech National Bank now owns 9,025 shares of the medical research company’s stock valued at $2,445,000 after buying an additional 41 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its position in Charles River Laboratories International by 1.0% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 4,424 shares of the medical research company’s stock worth $914,000 after purchasing an additional 45 shares in the last quarter. Tortoise Investment Management LLC boosted its position in Charles River Laboratories International by 77.0% in the 2nd quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock worth $27,000 after purchasing an additional 57 shares in the last quarter. Dumont & Blake Investment Advisors LLC boosted its position in Charles River Laboratories International by 1.4% in the 1st quarter. Dumont & Blake Investment Advisors LLC now owns 4,415 shares of the medical research company’s stock worth $1,196,000 after purchasing an additional 62 shares in the last quarter. Finally, Mitchell & Pahl Private Wealth LLC boosted its position in Charles River Laboratories International by 2.0% in the 2nd quarter. Mitchell & Pahl Private Wealth LLC now owns 3,154 shares of the medical research company’s stock worth $652,000 after purchasing an additional 62 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on CRL shares. Evercore ISI reduced their target price on Charles River Laboratories International from $265.00 to $225.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. Barclays reduced their target price on Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating for the company in a research note on Thursday, August 8th. The Goldman Sachs Group reduced their target price on Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating for the company in a research note on Thursday, August 8th. Mizuho started coverage on Charles River Laboratories International in a research note on Friday, June 7th. They set a “neutral” rating and a $235.00 target price for the company. Finally, Argus reaffirmed a “hold” rating on shares of Charles River Laboratories International in a research note on Friday, June 28th. Ten equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Charles River Laboratories International has a consensus rating of “Hold” and an average price target of $227.55.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $203.83 on Tuesday. The stock has a market cap of $10.50 billion, a PE ratio of 23.98, a P/E/G ratio of 3.89 and a beta of 1.36. The company has a current ratio of 1.58, a quick ratio of 1.21 and a debt-to-equity ratio of 0.65. Charles River Laboratories International, Inc. has a twelve month low of $161.65 and a twelve month high of $275.00. The stock has a fifty day simple moving average of $209.09 and a 200-day simple moving average of $223.05.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share for the quarter, topping analysts’ consensus estimates of $2.39 by $0.41. The business had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.03 billion. Charles River Laboratories International had a return on equity of 14.96% and a net margin of 10.83%. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 10.01 earnings per share for the current year.

Charles River Laboratories International declared that its board has authorized a share repurchase program on Wednesday, August 7th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the medical research company to purchase up to 9.6% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s management believes its stock is undervalued.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).